ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 371

Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis

Takahiko Sugihara1, Tatsuro Ishizaki2, Tadashi Hosoya1, Shoko Iga1, Waka Yokoyama1, Fumio Hirano1, Nobuyuki Miyasaka3 and Masayoshi Harigai4, 1Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 2Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, 3Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 4Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: joint destruction, physical function, remission, rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical practice is insufficient. The objective of this study was to evaluate structural damage and physical disability of patients who developed RA at ≥60 y/o (elderly onset RA, EORA) and were treated aiming at low disease activity (LDA) in Choju registry of rheumatoid arthritis on non-biologic and biologic disease-modifying antirheumatic drugs (DMARDs) for elderly patients in Japan (CRANE), a prospective, mono-centric registry.

Methods: Of 150 Japanese elderly (≥60 years) patients with RA enrolled in the CRANE, we identified 106 methotrexate-naïve EORA patients with moderate to severe disease activity (disease activity score 28 joints (DAS28)≥ 3.2) and disease duration ≤ 3 years at the enrollment. We analyzed data from 84 patients who completed 12-month follow-up in this study. The treatment was adjusted every 3 months aiming at LDA (DAS28< 3.2). We started treatment with non-biologic DMARD monotherapy (methotrexate (MTX), tacrolimus, salazosulfapyridine, or bucillamine), followed by TNF inhibitors, then tocilizumab or abatacept. The co-primary outcomes were DAS28, Δtotal sharp score (TSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) at week52.   

Results: Baseline characteristics of the 84 patients were as follows: mean age, 75.3 y/o; mean disease duration, 0.92 years; mean DAS 28, 6.33; mean HAQ, 1.23; anti-CCP antibody positive, 66.3%. Rates for comorbidity of the patients were 33.8% for chronic lung diseases, 12.8% for cardiovascular diseases and16.3% for diabetes mellitus. At week 12, 77.6% and 14.1% of the patients were receiving MTX at 7.3±1.8 mg/week and tacrolimus, respectively. At weeks 24 and 52, 16.9% and 33.3 % of the patients were treated with TNF inhibitors. LDA and functional remission (HAQ-DI≤0.5) were achieved in 29.1% and 42.6% of the patients at week 24, respectively, and in 45.9% and 58.1% at week 52, respectively. Structural remission (ΔTSS/year≤ 0.5) were observed in 39.3 % and rapid radiographic progression (RRP,ΔTSS/year>3) in 32.6% of the patients. Triple (clinical, structural and functional) remission at week 52 was observed in 8.3% of the patients. Mean DAS28 at weeks 0, 12 and 24 and mean HAQ-DI at week 52 was significantly higher in the patients with RRP compared to those without RRP. The multiple logistic regression model involving the area under the curve (AUC) of DAS28 (accumulated DAS28) between week 0 and week 12, as well as age, sex, anti-CCP antibody status, HAQ-DI, and presence of bony erosions at week 0, predicted RRP at week 52 well with the C statistic of 0.897, and the AUC of DAS28 during the first 3 months predicted RRP better than those during the first 6 or 12 months (the C-statistic, 0.879 for 0-6 months, and 0.834 for 0-12 months).

Conclusion: Achieving LDA, structural remission and functional remission in daily clinical practice using non-biologic and biologic DMARDs in EORA patients were realistic goals. Rapid achievement and sustainment of clinical remission is indispensable to prevent RRP in the patients with EORA.


Disclosure:

T. Sugihara,

Takeda Pharmaceutical Co. Ltd,

2;

T. Ishizaki,
None;

T. Hosoya,
None;

S. Iga,
None;

W. Yokoyama,
None;

F. Hirano,
None;

N. Miyasaka,
None;

M. Harigai,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treat-to-target-strategy-aiming-at-achievement-of-structural-and-functional-remission-in-patients-with-active-elderly-onset-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies